✨ Free AI Report
20/20 Biolabs, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview 20/20 Biolabs, Inc.
Research Preview

20/20 Biolabs, Inc.: Business Overview, Financials & Competitive Analysis

20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company provides OneTest for Cancer, a multi-cancer early ...

Analyst-debate audio for 20/20 Biolabs, Inc.

AskCyborg analysts argue the bull and bear cases for 20/20 Biolabs, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
20/20 Biolabs, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Early-stage MCED player with pricing and convenience advantages, but scale and profitability risks limit near-term upside in a...

Read the full analyst-debate transcript →
Industry Diagnostic Laboratories
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest 20/20 Biolabs, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

20/20 Biolabs, Inc. Overview

Pro stress-test →

20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company provides OneTest for Cancer, a multi-cancer early detection (MCED) blood test, and OneTest for Longevity, which measures inflammatory biomarkers. The company operates as a commercial-stage diagnostics firm leveraging machine learning to differentiate its offerings in the early disease detection market.

Strategic Profile

Pro stress-test →

20/20 Biolabs pioneers affordable, accurate, actionable tests that can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. The company operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups, and was formerly known as 20/20 GeneSystems, Inc., changing its name in March 2025. Its competitive positioning emphasizes cost advantages—starting at under $200, versus just under $1,000 from leading competitors—and at-home sampling convenience.

Competitive Landscape

Pro stress-test →

20/20 Biolabs competes in the multi-cancer early detection (MCED) diagnostics market against established players offering DNA-based tests, as well as emerging clinical laboratory and AI-driven diagnostics companies. The company differentiates on pricing (under $200 vs. ~$1,000), at-home sample collection, and proprietary machine learning algorithms applied to blood biomarkers. Key competitive pressures include larger, better-capitalized MCED developers, reimbursement uncertainty, and clinical validation demands.

Industry Context

20/20 Biolabs, Inc. operates in Diagnostic Laboratories.

Key facts

Founded: 2000 · Headquarters: Gaithersburg, Maryland · Employees: 19

What the analysts stress-tested

The top findings that survived the multi-agent debate for 20/20 Biolabs, Inc..

+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when 20/20 Biolabs, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GrailMulti-cancer early detection blood test (Galleri)→Exact SciencesCancer screening and molecular diagnostics→Guardant HealthMulti-cancer early detection platform→BiodesixAI-driven blood-based diagnostics for cancer→

Compare 20/20 Biolabs, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

20/20 Biolabs, Inc. operates in Diagnostic Laboratories. See how the rest of the sector scores on the Cyborg framework.

Browse Diagnostic Laboratories research →
NEW · MCP server

Ask your AI assistant about 20/20 Biolabs, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 20/20 Biolabs, Inc. and its top competitor on Cyborg Score”
“What did 20/20 Biolabs, Inc. do this quarter?”
“Is 20/20 Biolabs, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does 20/20 Biolabs, Inc. do?+
20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company provides OneTest for Cancer, a multi-cancer early ...
What is 20/20 Biolabs, Inc.'s Cyborg Score?+
20/20 Biolabs, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 20/20 Biolabs, Inc.'s main competitors?+
Named competitors include Grail, Exact Sciences, Guardant Health, Biodesix. The full competitive landscape is in the AskCyborg report.
How can I get the full 20/20 Biolabs, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 20/20 Biolabs, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 20/20 Biolabs, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Diagnostic Laboratories research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5GRAIL, Inc.6Biodesix, Inc.